På dette tidspunkt var CHMP af den opfattelse, at fordelene ved Valdoxan/ Thymanax ikke opvejede risiciene.
At this point in time, the CHMP was of the opinion that the benefits of Valdoxan/ Thymanax did not outweigh its risks.